<DOC>
	<DOCNO>NCT00069641</DOCNO>
	<brief_summary>The purpose study determine whether administration iduronate-2-sulfatase enzyme weekly every week therapy frequency safe efficacious patient MPS II .</brief_summary>
	<brief_title>Iduronate-2-sulfatase Enzyme Replacement Therapy Mucopolysaccharidosis II ( MPS II )</brief_title>
	<detailed_description>MPS II rare , X-linked , lysosomal storage disorder cause deficiency enzyme iduronate-2-sulfatase . Because deficiency , glycosaminoglycans ( GAG ) accumulate multiple tissue organ , result progressive cellular organ system dysfunction . The purpose study determine one year therapy iduronate-2-sulfatase enzyme replacement therapy , dose 0.5mg/kg , weekly every week , safe , result clinically meaningful improvement multiple organ function , compare placebo group . Upon completion study , patient eligible enroll open-label maintenance study .</detailed_description>
	<mesh_term>Mucopolysaccharidoses</mesh_term>
	<mesh_term>Mucopolysaccharidosis II</mesh_term>
	<criteria>To eligible participate study , patient must meet follow inclusion criterion prior enrollment : 1 . The diagnosis MPS II determine investigator base upon clinical biochemical criterion . 2 . All patient must least one follow Clinical Criteria consider investigator MPS IIrelated : Hepatosplenomegaly Radiographic evidence dysostosis multiplex Valvular heart disease Evidence obstructive pulmonary disease 3 . In addition , patient must follow Biochemical Criteria : Documented deficiency iduronate2sulfastase enzyme activity less equal 10 % low limit normal range measure plasma , fibroblast , leukocyte ( base normal range measure laboratory ) . A normal enzyme activity level one sulfatase measure plasma , fibroblast , leukocyte ( base normal range measure laboratory ) . 4 . Must male , 5 25 year age . 5 . Forced vital capacity &lt; 80 % predict obtained baseline evaluation study . 6 . Must able adequately perform testing require study , include reproducible pulmonary function test spirometry , judge investigator . 7 . Patient , patient 's parent ( ) , legally authorize guardian must voluntarily sign Institutional Review Board ( IRB ) /Independent Ethics Committee ( IEC ) approve informed consent form relevant aspect study explain discussed patient . Patients meet follow criterion eligible participation study : 1 . Patient receive treatment another investigational therapy within past 60 day . 2 . Patient , patient 's parent ( ) , patient 's legal guardian unable understand nature , scope , possible consequence study . 3 . Patient unable comply protocol ( e.g. , due medical condition cervical cord compression uncooperative attitude ) unlikely complete study , determine investigator . 4 . Patient tracheostomy . 5 . Patient receive bone marrow cord blood transplant . 6 . Patient known hypersensitivity component iduronate2sulfatase .</criteria>
	<gender>Male</gender>
	<minimum_age>5 Years</minimum_age>
	<maximum_age>25 Years</maximum_age>
	<verification_date>January 2014</verification_date>
	<keyword>Mucopolysaccharidosis II</keyword>
	<keyword>MPS II</keyword>
	<keyword>Hunter Syndrome</keyword>
	<keyword>iduronate-2-sulfatase</keyword>
	<keyword>I2S</keyword>
	<keyword>Iduronate-2-sulfatase deficiency</keyword>
</DOC>